4d agoThe FlyNEUTRAL 50General
Archived explainer. For the current picture see today's IMVT page.
Why Is IMMUNOVANT INC (IMVT) Stock Up Today?
By the Top Tier Newswire AI Desk · November 9, 2026 at 9:40 AM ET · reviewed against 6 wire stories
IMMUNOVANT INC (IMVT) is up +12.28% in the latest session. Our newswire has captured 6 stories on IMVT across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 51/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
IMVT shares rose 12.28% to $34.28 as the company reported second quarter results that exceeded expectations. The primary driver was a GAAP EPS of -$0.47, which beat the consensus estimate of -$0.72 by $0.27.
What Happened
Immunovant reported its financial results for the quarter ended September 30, 2026, via an 8-K filing. The company’s net loss narrowed, and research and development spending decreased, contributing to the positive earnings surprise. In a separate filing, Immunovant registered an automatic mixed securities shelf, though specific terms were not disclosed. The stock had already shown momentum prior to the report, moving up 3.8% over the previous eight sessions.
What The Data Shows
The stock opened at $32.18, a 5.4% gap up from the prior close of $30.53. It reached a session high of $35.86 at 7:05 AM ET before settling near $34.60. Volume was 0.3M shares, which is 0.2x the three-month daily average. The company has a market capitalization of $6.3B and remains unprofitable with a trailing twelve months EPS of -2.82. The 52-week range is $21.43 to $45.42. On November 9, 2026, the stock printed four fresh 52-week highs and one fresh 52-week low. Insider activity has been selling-heavy, with nine sales totaling $923K in the last 90 days and no buys. Recent sales were executed by CFO Girao Tiago, CTO Jay S Stout, and COO Melanie Gloria.
What To Watch
Investors will monitor the company’s upcoming earnings date and the utilization of the newly filed mixed securities shelf.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IMVT by the numbers
Last: $34.28Session: +12.28%7 sessions: +18.59%Coverage: 6 stories / 5 sourcesAI sentiment: 51/100 (mixed)Mkt cap: $6.3B52w: $21.43 to $45.42
The headlines behind the move
4d agoThe FlyBEARISH 34Earnings
Immunovant reports Q2 EPS (47c), consensus (72c)
4d agoBarron'sBULLISH 58General
S&P 500 Futures Up in Premarket Trading; Immunovant, Roivant Sciences Lead
4d agoSeeking AlphaBULLISH 63Earnings
Immunovant GAAP EPS of -$0.47 beats by $0.27
Immunovant Q2 earnings beat estimates as net loss narrowed and R&D spending fell.
4d agoSEC 8-KNEUTRAL 50General
Immunovant, Inc. (IMVT) files 8-K
Filed: 2026-11-09 AccNo: 0001764013-26-000121 Size: 300 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
4d agoStockTitanNEUTRAL 53Earnings
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on IMVT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IMVT move explainers: 2026-11-10 · 2026-11-09 · 2026-09-23